Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Organisation › Details

CureVac N.V. (Nasdaq: CVAC)

CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S. *

 

Period Start 2020-08-10 existent
  Group CureVac (Group)
  Predecessor CureVac AG
Products Industry mRNA technology
  Industry 2 mRNA-based drug
Persons Person Zehnder, Alexander (CureVac 202304– CEO before Sanofi + Roche/Genetech)
  Person 2 Stéphenne, Jean (GSK Biologicals 200512 President)
     
Region Region Tübingen
  Country Germany
  Street 15 Friedrich-Miescher-Str.
  City 72076 Tübingen
  Tel +49-7071-9883-0
    Address record changed: 2023-07-23
     
Basic data Employees F: 1,001 to 5,000 (2023-07-14)
  Currency EUR
  Annual sales 102,990,000 (revenue, annual, consolidated (2021) 2021-12-31)
  Profit -411,716,000 (2021-12-31)
  Cash 537,900,000 (2023-06-30)
     
    * Document for »About Section«: CureVac N.V.. (7/14/23). "Press Release: CureVac Announces Update to the Management Team". Tübingen & Boston, MA.
     
   
Record changed: 2024-04-29

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for CureVac (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px




» top